Skip to main content

04-06-2019 | Non-small cell lung cancer | ASCO 2019 | Article

Expert comment: 5-year update of KEYNOTE-001

Conference coverage direct to your inbox

ASCO expert David Graham tells us just why he thinks the 5-year survival data from the advanced non-small-cell lung cancer patients enrolled in the phase Ib KEYNOTE-001 trial are so remarkable (1:26).

Back to the conference hub​​​​​​​

Related topics

More on this topic

Image Credits